3 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Recruiting 1 |
Follow avibactam: new trials by email Literature Review of avibactam trials Research Report on avibactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Not yet recruiting | BioVersys AG | 120 | 2026-07-01 | 2026-02-24 |
| Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections ATM-AVI, BAT - Gram-negative Bacterial Infections | Phase 2 | Recruiting | Pfizer | 48 | 2023-04-18 | 2026-10-29 |
| Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem - Urinary Tract Infections | Phase 2 | Completed | Forest Laboratories | 217 | 2010-12-01 | 2014-02-03 |
| Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections ceftazidime/NXL104 + metronidazole, meropenem - Complicated Intra-abdominal Infections | Phase 2 | Completed | Pfizer | 204 | 2009-03-31 | 2018-07-03 |
| Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections NXL104/ceftazidime, Imipenem/Cilastatin - Complicated Urinary Tract Infection | Phase 2 | Completed | Pfizer | 137 | 2008-11-01 | 2018-05-25 |
Central Nervous System Infections (1) · Cerebral Ventriculitis (1) · Gram-Negative Bacterial Infections (1) · Meningitis, Bacterial (1) · Urinary Tract Infections (1)
Pfizer (3) · BioVersys AG (1) · Forest Laboratories (1)
United States (4) · Lebanon (3) · Bulgaria (2) · India (2) · Poland (2) · Russia (2) · Turkey (Türkiye) (2) · China (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Jordan (1) · Romania (1) · Spain (1)